Caroline Robert
Université Paris-Sud · 1,621 works · 161,901 citations · h-index 161
Top works
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group
- Immune-related adverse events with immune checkpoint blockade: a comprehensive review
- Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
- Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma